Boen Monica, Alhaddad Marwan, Goldman Mitchel P, Kollipara Ramya, Hoss Elika, Wu Douglas C
Cosmetic Laser Dermatology, San Diego, California.
University of California, San Diego, California.
Dermatol Surg. 2022 Jan 1;48(1):76-81. doi: 10.1097/DSS.0000000000002582.
Jawline augmentation with calcium hydroxylapatite has not yet been evaluated in a prospective study with a split-face design. This study aims to perform the first randomized controlled, split-face study on the efficacy and safety of calcium hydroxylapatite for jawline augmentation using the needle and cannula technique.
To perform the first randomized controlled, split-face study on the efficacy and safety of calcium hydroxylapatite for jawline augmentation using the needle and cannula technique.
This is a single-site, randomized, evaluator-blind trial enrolling a total of 10 healthy subjects with at least Grade 1 (mild) on a 4-point Jawline Scale. One side of the face was randomized to receive 1 to 2 syringes of calcium hydroxylapatite with lidocaine (total of 3 mL) for correction of wrinkles and folds along the jawline using both the cannula and needle method, and a balancing treatment will be performed 1 month later. Blinded investigator and subject evaluations will be performed immediately after treatment and at the 30-, 60-, and 90-day visits.
Ten subjects were enrolled and completed the trial. There was a improvement in the degree of wrinkling and skin sagging in the 4-point Jawline Scale, with an average of a 1.3-point improvement in the scale on the day of treatment and at the Day 30 visit, which remained improved greater than baseline after 3 months as graded by blinded investigators. The Clinician Global Aesthetic Improvement Score for the treated side versus control, as assessed by blinded investigators, demonstrated a improvement with a 2.3-point improvement on the 5-point scale, and by the final visit on Day 90, most patients had a much improved appearance from baseline.
This study demonstrates that calcium hydroxylapatite is effective and safe for restoration and augmentation of the jawline using the unique needle and cannula technique.
羟基磷灰石用于下颌轮廓塑形尚未在一项采用半脸设计的前瞻性研究中得到评估。本研究旨在首次进行一项随机对照半脸研究,以评估羟基磷灰石采用针管技术用于下颌轮廓塑形的有效性和安全性。
首次进行一项随机对照半脸研究,以评估羟基磷灰石采用针管技术用于下颌轮廓塑形的有效性和安全性。
这是一项单中心、随机、评估者盲法试验,共纳入10名健康受试者,其下颌轮廓在4分制下颌轮廓量表中至少为1级(轻度)。将面部的一侧随机分配接受1至2支含利多卡因的羟基磷灰石(共3 mL),使用套管针和针方法矫正下颌轮廓沿线的皱纹和褶皱,1个月后进行对照治疗。在治疗后以及第30、60和90天访视时进行盲法研究者和受试者评估。
10名受试者入组并完成试验。4分制下颌轮廓量表中的皱纹程度和皮肤松弛情况有所改善,治疗当天和第30天访视时量表平均改善1.3分,3个月后经盲法研究者分级仍高于基线水平。由盲法研究者评估的治疗侧与对照侧的临床医生整体美学改善评分显示有改善,在5分制量表上提高了2.3分,到第90天最后一次访视时,大多数患者的外观较基线有很大改善。
本研究表明,使用独特的针管技术,羟基磷灰石用于下颌轮廓的修复和塑形是有效且安全的。